Terms: = Leukemia AND EIF3E, eIF3-p46, 3646, ENSG00000104408, EIF3S6, eIF3e, EIF3-P48, INT6 AND Treatment
4 results:
1. Allogeneic Human Double Negative T Cells as a Novel Immunotherapy for Acute Myeloid leukemia and Its Underlying Mechanisms.
Lee J; Minden MD; Chen WC; Streck E; Chen B; Kang H; Arruda A; Ly D; Der SD; Kang S; Achita P; D'Souza C; Li Y; Childs RW; Dick JE; Zhang L
Clin Cancer Res; 2018 Jan; 24(2):370-382. PubMed ID: 29074605
[No Abstract] [Full Text] [Related]
2. Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial.
Jaeger U; Trneny M; Melzer H; Praxmarer M; Nawarawong W; Ben Yehuda D; Goldstein D; Mihaljevic B; Ilhan O; Ballova V; Hedenus M; Hsiao LT; Au WY; Burgstaller S; Weidinger G; Keil F; Dittrich C; Skrabs C; Klingler A; Chott A; Fridrik MA; Greil R;
Haematologica; 2015 Jul; 100(7):955-63. PubMed ID: 25911553
[TBL] [Abstract] [Full Text] [Related]
3. Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma.
Ise T; Nagata S; Kreitman RJ; Wilson WH; Wayne AS; Stetler-Stevenson M; Bishop MR; Scheinberg DA; Rassenti L; Kipps TJ; Kyle RA; Jelinek DF; Pastan I
Leukemia; 2007 Jan; 21(1):169-74. PubMed ID: 17051241
[TBL] [Abstract] [Full Text] [Related]
4. treatment of early clinically staged Hodgkin's disease with a combination of ABVD chemotherapy plus limited field radiotherapy.
Karmiris TD; Grigoriou E; Tsantekidou M; Spanou E; Mihalakeas H; Baltadakis J; Apostolidis J; Pagoni M; Karakasis D; Bakiri M; Mitsouli C; Harhalakis N; Nikiforakis E
Leuk Lymphoma; 2003 Sep; 44(9):1523-8. PubMed ID: 14565654
[TBL] [Abstract] [Full Text] [Related]
